Imugene progresses onCARlytics solid tumour trial to combination arm

(3:4)

Imugene’s $20 million boost and cancer trial updates

(7:42)

Imugene’s $20 million boost and cancer trial updates

(7:42)

Imugene forges development path of immunotherapies and cancer-killing virus

(24:2)

Groundbreaking cancer trial: Imugene’s CF33 advances in clinical success

(16:2)

Imugene MAST trial delivers two-year complete response in bile tract cancer patient

(4:54)

Progressive Psy Trance EOYM 🕉 Vegas, Minority, Neelix, Naturalize, Zyrus7, Grynder, Henix-R, Poxell

(1:41:9)

Imugene Science Series With Dr Yuman Fong - November 2024

(20:20)

New Expedited Pathways: Streamlining Specialist IMGs into Australia

(6:13)

Imugene Investor Presentation | Non-deal Roadshow 2023 Australia

(44:28)

Interview With The CF33 Oncolytic Virus Inventor - Imugene (IMU)

(20:11)

Imugene achieves ‘complete response’ with mid dose cancer trial

(7:36)

Imugene steps up dosage at groundbreaking VAXINIA cancer trial

(19:3)

Imugene's CEO Leslie Chong presents at the 2023 JP Morgan Healthcare Conference in San Francisco.

(16:42)

Imugene Officially Announce Their HER-Vaxx Trial Results

(8:59)

Investor webinar: Azer-cel trial update, September 2024

(25:35)

Imugene Limited (ASX:IMU) Three Complete Responses in Azer-Cel Phase 1b Trial

(3:51)

Imugene begins VAXINIA trial for bile tract cancer

(10:)

Imugene (ASX: IMU) – The ‘Holy Grail’ Of Cancer Treatment…?! | ASX CEO Interview 🚀📈

(20:37)

How Imugene is Turning Viruses into Cancer-Fighting Heroes!

(32:27)

Imugene secures IND approval for first-in-class onCARlytics trial

(5:40)

Imugene Limited (ASX: IMU) Emergence 2024: Presentation by Leslie Chong, Managing Director and CEO

(7:40)

'The Why' | Imugene, Developing Cancer Immunotherapies ASX: IMU

(4:51)

Imugene's Science Series: PD1-Vaxx | B cell immunotherapy

(32:59)

Imugene finishes Phase 1a monotherapy dose escalation of PD1 Vaxx

(6:29)

Imugene welcomes dosing of first patient in nextHERIZON Phase 2 clinical trial

(5:20)

Imugene progresses onCARlytics solid tumour trial to combination arm

(3:4)

Imugene Investor Webinar: MAST Study Update

(27:13)

Imugene bringing effective new treatments and options to cancer patients

(11:25)